In our interview, Dr. Lukas Leu, Healthcare Analyst, explains how groundbreaking the approval of Biogen's Alzheimer's drug Aduhelm is for research in this difficult disease. Read more in our latest «Healthcare Observer».

«Best-case scenario: three products approved by the end of 2022»

In our interview, Dr. Lukas Leu, Healthcare Analyst, explains how groundbreaking the approval of Biogen's Alzheimer's drug Aduhelm is for research in this difficult disease. Read more in our latest «Healthcare Observer».
30.09.2021 - Bellevue Asset Management